Status:
COMPLETED
Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer
Lead Sponsor:
City of Hope Medical Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-120 years
Phase:
PHASE1
Brief Summary
RATIONALE: Diagnostic procedures, such as immunoscintigraphy, using a radiolabeled monoclonal antibody may help find and diagnose colorectal cancer. PURPOSE: This clinical trial is studying how well ...
Detailed Description
OBJECTIVES: Primary * To determine the ability of iodine I 123 anti-CEA recombinant diabody T84.66 to localize to colorectal cancer, as determined by quantitative radioimmunoscintigraphy in patients...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed colorectal cancer
- Stage I-IV disease
- PATIENT CHARACTERISTICS:
- Serum creatinine \< 2.0 mg/dL
- Total bilirubin \< 2.0 mg/dL
- Hemoglobin \> 9.0 g/dL
- cT84.66 antibody negative (if previously treated with mouse or chimeric immunoglobulins)
- Not pregnant
- No condition that, in the opinion of the investigator, would preclude study compliance
- No known allergy to iodine
- No known history of HIV, hepatitis B, or hepatitis C
- PRIOR CONCURRENT THERAPY:
- No concurrent steroids
Exclusion
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00647153
Start Date
May 1 2006
End Date
October 1 2012
Last Update
November 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010-3000